Vsevolod Matveev

A Prospective, Randomised EORTC Intergroup Phase 3 Study Comparing the Oncologic Outcome of Elective Nephron-Sparing Surgery and Radical Nephrectomy for Low-Stage Renal Cell Carcinoma

Hendrik Van Poppel, L. Da Pozzo, Walter Albrecht et al. · European Urology · 2010 · 1K citations

Medicine, Oncology, Surgery +16

A Prospective Randomized EORTC Intergroup Phase 3 Study Comparing the Complications of Elective Nephron-Sparing Surgery and Radical Nephrectomy for Low-Stage Renal Cell Carcinoma

Hendrik Van Poppel, L. Da Pozzo, Walter Albrecht et al. · European Urology · 2006 · 1K citations

Medicine, Oncology, Surgery +16

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Michiel S. van der Heijden, Matthew D. Galsky, Yohann Loriot et al. · The Lancet Oncology · 2020 · 498 citations · Full text

Medicine, Oncology, Pharmacology +14

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial

Matthew R. Smith, Chris Parker, Fred Saad et al. · The Lancet Oncology · 2019 · 397 citations · Full text

Medicine, Oncology, Urology +16

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial

Ian F. Tannock, Karim Fizazi, Camilla Thellenberg Karlsson et al. · The Lancet Oncology · 2013 · 287 citations

Medicine, Oncology, Pharmacology +16